Order Article Reprints

Masuda N, Yoshinami T, Ikeda M, Mizutani M, Yamaguchi M, Komoike Y, Takashima T, Yoshidome K, Tsurutani J, Iwamoto M, et al. Capecitabine in Combination with Endocrine Therapy as Maintenance Therapy after Bevacizumab Plus Paclitaxel Induction Therapy for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: KBCSG-TR1214. Cancers. 2021; 13(17):4399. https://doi.org/10.3390/cancers13174399

Masuda, Norikazu, Tetsuhiro Yoshinami, Masahiko Ikeda, Makiko Mizutani, Miki Yamaguchi, Yoshifumi Komoike, Tsutomu Takashima, Katsuhide Yoshidome, Junji Tsurutani, Mitsuhiko Iwamoto, and et al. 2021. "Capecitabine in Combination with Endocrine Therapy as Maintenance Therapy after Bevacizumab Plus Paclitaxel Induction Therapy for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: KBCSG-TR1214" Cancers 13, no. 17: 4399. https://doi.org/10.3390/cancers13174399

Masuda, N., Yoshinami, T., Ikeda, M., Mizutani, M., Yamaguchi, M., Komoike, Y., Takashima, T., Yoshidome, K., Tsurutani, J., Iwamoto, M., Fujisawa, F., Yasojima, H., Yamamura, J., Morishima, H., Aki, F., Yamada, T., Morita, S., & Nakayama, T. (2021). Capecitabine in Combination with Endocrine Therapy as Maintenance Therapy after Bevacizumab Plus Paclitaxel Induction Therapy for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: KBCSG-TR1214. Cancers, 13(17), 4399. https://doi.org/10.3390/cancers13174399